Contamination Control Strategy: Implementation Road Map

Reference

1. 1.↵
   European Commission. Second targeted stakeholders' consultation on the draft revision 12 of Annex 1, on manufacturing of sterile medicinal products, of Eudralex, Vol. 4, 2020. https://ec.europa.eu/health/medicinal_products/consultations/2020_sterile_medicinal_products_en (accessed June 10, 2020).
2. 2.↵
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical Quality System Q10, 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf (accessed September 8, 2020).
3. 3.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2014; Chapter 3: Premises and Equipment. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/chapter_3.pdf (accessed February 10, 2021).
4. 4.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2014; Chapter 5: Production. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/chapter_5.pdf (Accessed Feb 10, 2021).
5. 5.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2014; Part II: Basic Requirements for Active Substances used as Starting Materials. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/2014-08_gmp_part1.pdf (Accessed February 10, 2021).
6. 6.↵
   European Union. Guidelines of 19 March 2015 on the Formalised Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal Products for Human Use. Official Journal of the European Union. 2015, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0321(02)&from=EN (Accessed September 8, 2020).
7. 7.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2018, Annex 2: Manufacture of Biological Active Substances and Medicinal Products for Human Use. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/pdfs-en/2018_annex2_en.pdf (accessed March 2, 2021).
8. 8.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2008, Annex 3: Manufacture of Radiopharmaceuticals. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/2008_09_annex3_en.pdf (Accessed March 2, 2021).
9. 9.↵
   European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. 2011, Annex 14 Manufacture of Medicinal Products Derived from Human Blood or Plasma. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/annex14_rev30-03_2011_en.pdf (Accessed March 10, 2021).
10. 10.↵
    European Commission, Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines, 2017, Guidelines on Good Manufacturing Practice Specific to Advanced Therapy Medicinal Products. https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf (Accessed March 10, 2021).
11. 11.↵
    European Union. Guidelines of 5 November 2013 on Good Distribution Practice of Medicinal Products for Human Use. Official Journal of the European Union 2013, 1–14. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C_.2013.343.01.0001.01.ENG&toc=OJ:C:2013:343:TOC (Accessed August 2, 2021).
12. 12.↵
    European Union. Guidelines of 19 March 2015 on Principles of Good Distribution Practice of Active Substances for Medicinal Products for Human Use. Official Journal of the European Union 2015, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0321(01)&from=EN5 (accessed August 2, 2021).
13. 13.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart C: Building and Facilities, sec. 211.42 Design and Construction Features, (b), (c). U.S. Food & Drug Administration, 2012. https://www.govinfo.gov/content/pkg/CFR-2012-title21-vol4/pdf/CFR-2012-title21-vol4-sec211-42.pdf (Accessed March 8, 2021).
14. 14.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart F: Production and Process, Controls, sec. 211.113 Control of Microbial Contamination (a), (b). U.S. Food & Drug Administration, 1996. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.113 (Accessed March 8, 2021).
15. 15.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart B: Organization and Personnel, sec.211.28 Personnel Responsibilities (a). U.S. Food & Drug Administration, 1996. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.28 (Accessed March 8, 2021).
16. 16.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart E: Control of Components and Drug Product Containers and Closures, sec. 211.80 General Requirements (b). U.S. Food & Drug Administration, 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.80 (Accessed April 8, 2021).
17. 17.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart E: Control of Components and Drug Product Containers and Closures, sec. 211.84 Testing and Approval or Rejection of Components, Drug Product Containers, and Closures (d). U.S. Food & Drug Administration, 2011. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.84 (Accessed March 8, 2021).
18. 18.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart D: Equipment, sec. 211.67 Equipment Cleaning and Maintenance (a). U.S. Food & Drug Administration, 2011. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.67 (Accessed December 10, 2021).
19. 19.↵
    Current Good Manufacturing Practice for Finished Pharmaceuticals. Code of Federal Regulations, Part 211, Title 21, Subpart C: Buildings, and Facilities, sec. 211.56 Sanitation (c). U.S. Food & Drug Administration, 2012. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.56 (Accessed December 10, 2021).
20. 20.↵
    Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. 2004. U.S. Department of Health and Human Services, Food and Drug Administration. https://www.fda.gov/media/71026/download (Accessed September 9, 2020).
21. 21.↵
    Guidance for Industry: Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing. 2020. U.S. Department of Health and Human Services, Food and Drug Administration. https://www.fda.gov/media/139299/download (Accessed March 8, 2021).
22. 22.↵
    Guidance for Industry: Non-Penicillin Beta-Lactam Drugs, A CGMP Framework for Preventing Cross Contamination. 2013. U.S. Department of Health and Human Services, Food and Drug Administration. https://www.fda.gov/files/drugs/published/Non-Penicillin-Beta-Lactam-Drugs--A-CGMP-Framework-for-Preventing-Cross-Contamination.pdf (Accessed March 8, 2021).
23. 23.↵
    Guidance for Industry: Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration, 2020. https://www.fda.gov/media/88905/download (accessed January 6, 2021).
24. 24.↵
    U. S. Pharmacopeial Convention. General Chapter <1115> Bioburden Control of Nonsterile Drug Substances and Products. In USP 41–NF 36, USP: Rockville, MD, 2018.
25. 25.↵
    U. S. Pharmacopeial Convention. General Chapter <1116> Microbiological Control and Monitoring of Aseptic Processing Environments. In USP 41–NF 36, USP: Rockville, MD, 2013.
26. 26.↵
    1. Sandle T. E. A.

    Contamination Control Strategy for Aseptic Processing, 2017. http://www.americanpharmaceuticalreview.com/Featured-Articles/335458-Establishing-a-Contamination-Control-Strategy-for-Aseptic-Processing/ (accessed June 10, 2020).
27. 27.↵
    1. Schmit S.

    Developing an Effective Contamination Control Strategy, 2019. http://www.pharmtech.com/developing-effective-contamination-control-strategy-0 (accessed June 10, 2020).
28. 28.↵
    1. Santos A.,
    2. Doria M.,
    3. Meirinhos-Soares L.,
    4. Almeida A.,
    5. Menezes J.

    A QRM Discussion of Microbial Contamination of Non-Sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016. PDA J. Pharm. Sci. Technol. 2018, 72(1), 62–72.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Johnson L.,
    2. Hansy C.

    Establishing a Contamination Control Strategy/Program: From Global Development to Site Implementation, 2020. https://www.americanpharmaceuticalreview.com/Featured-Articles/564173-Establishing-a-Contamination-Control-Strategy-Program-From-Global-Development-to-Site-Implementation/?catid=6262 (accessed June 10, 2020).
30. 30.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Pharmaceutical Development, Q8(R2), August 2009. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf (accessed December 11, 2020).
31. 31.↵
    1. Haddad G.,
    2. Greene A.

    Quality Risk Management Competency Model—Case for the Need for QRM Competencies. PDA Journal of Pharmaceutical Science and Technology 2019, 73 (4), 331–344.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Cundell T.,
    2. Drummond S.,
    3. Ford I.,
    4. Reber D.,
    5. Singer D.

    Risk Assessment Approach to Microbiological Controls of Cell Therapies. PDA J. Pharm. Sci. Technol. 2020, 74(2), 229–248.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12, 2019. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf (accessed June 10, 2020).
34. 34.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Quality Risk Management Q9. November 2005. https://database.ich.org/sites/default/files/Q9%20Guideline.pdf (accessed September 8, 2020).
35. 35.↵
    European Commission. Eudralex, Vol. 4, Good Manufacturing Practice (GMP) Guidelines. In The Rules Governing Medicinal Products in the European Union. Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. January 2013; Chapter 1: Pharmaceutical Quality System. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/vol4-chap1_2013-01_en.pdf (accessed December 11, 2020).
36. 36.↵
    1. Dev S. K.,
    2. Srivastava S.

    Failure Mode and Effect Analysis (FMEA) Implementation: A Literature Review. J. Adv. Res. Aero. Space Sci. 2018, 5(1&2), 1–17.

    OpenUrl
37. 37.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Draft Guidance for Industry: Request for Quality Metrics, July 28, 2015.